The data comes from a phase 2/3 trial involving 2,246 adults.
Pfizer shared the trial data with the FDA as part of its ongoing rolling submission for the pill’s emergency use authorization. The agency has yet to schedule an advisory committee meeting to review the application.
The company also said lab studies suggest Paxlovid is effective against the omicron variant, though more research must be conducted.
The news comes as preliminary studies emerge on the Pfizer vaccine’s effectiveness against omicron. Two recent studies, one from the University of Oxford and one from the Israeli Health Ministry, suggest Pfizer’s booster provides a much stronger immune response against the omicron variant than its two-shot series alone.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
